{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-000859","form_type":"8-K","ticker":"BBNX","cik":"0001674632","company_name":"Beta Bionics, Inc.","filed_at":"2026-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.856930+00:00","generated_at":"2026-05-16T02:27:06.182720+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Beta Bionics Q4 2025 revenue $32.1M (+57% YoY); guides FY2026 $130-135M","bullets":["Net sales $32.1M in Q4 (+57% YoY); full year $100.3M (+54%). Installed base 35,011 users (+129%).","Gross margin 59% Q4 (up 179bps); FY gross margin 55.4%. Net loss $13.5M Q4 (improved from $18.1M).","2026 guidance: revenue $130M-$135M; PBP channel 36-38% of new starts; gross margin 55.5%-57.5%.","Bihormonal system Phase 2a first-in-human trial completed in New Zealand; additional Phase 2a expected H1 2026.","Cash $264.7M as of Dec 31, 2025. New patient starts up 37% Q4 to 5,592."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-000859","json":"https://secwatch.observer/filing/0001171843-26-000859.json","markdown":"https://secwatch.observer/filing/0001171843-26-000859.md","text":"https://secwatch.observer/filing/0001171843-26-000859.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674632/000117184326000859/0001171843-26-000859-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674632/000117184326000859/f8k_021326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:27:06.182720+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}